Discover and read the best of Twitter Threads about #regulator

Most recents (4)

Don’t forget that #tether invested in #celsiusnetwork
Celsius banked with #deltec and cashed out #ftx for $150m just before the ship went down.
Don't forget #deltec's bestest operator. gamer boy #pepin.
Read 12 tweets
Hetan's right. #Transparency alone is insufficient, and his combined proposals provide a far better framing for how to achieve #AlgorithmicAccountability.

A few thoughts:

On #piloting, or what in medicine would be called #ClinicalTrials, to check solely for #bias is missing...
...the point. #Bias is just one side-effect; trials must (in stages) test for any and all - so the general approach must attend first to #safety (including 'rights impacts'), then to #efficacy, then #effectiveness.

While I agree publishing models may be of limited use, it is...
...still important that they are - if only to establish the principle that they can be forensically analysed when something has gone wrong, not hidden behind '#CommercialConfidentiality', etc.

Publishing the #provenance of the training dataset, and assumptions, is vital however!
Read 6 tweets
1. "Absolute devastation": The whistleblower who will "never work again" after helping tax watchdog. @Adele_Ferguson

Ron Shamir has a lot to be angry about...

#Auspol #whiatlebkower @OZloop @Senator_Patrick @ATO_gov_au @Insp_Gen_Tax @LouiseBeaston

smh.com.au/business/workp…
2. At a Senate inquiry into the performance of the Inspector General of Taxation, which acts as the watchdog for the Australian Taxation Office, the whistleblower outlined how the system had failed him.

#Auspol @Insp_Gen_Tax @ATO_gov_au
3. “The result has been absolute devastation… My family and I have been living in poverty and I have been told by experts I will never work again,” he told the Senate committee.

Shamir became a whistleblower after he witnessed misconduct in the @ATO_gov_au relating...
Read 25 tweets
- Pharma MNCs riding on innovation & operating in niche therapies (less competition), focus on few brand & enjoy premium pricing, 100% focus on India market.
- Indian cos; struggle with regulatory hurdles (US FDA), 70% revenue from overseas biz, currency & geopolitical risks. Image
Indian pharma companies are facing a lot of compliance issues. If current situation continues, they might not get approval of pending products which ultimately impact on topline of these companies
#Lupin
#AurobindoPharma
#Cipla

@caniravkaria @_N_U_P_K_Y
Pfizer Q2 sales 567crs vs 519 crs, net profits up 60% at 154 crs vs 96

As mentioned, Pharma MNCs are exceedingly doing well compared to Indian pharma players!!

#Pfizer
#Abbott
#Merck
#Sanofi
#Glaxosmith
Read 10 tweets

Related hashtags

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3.00/month or $30.00/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!